Supreme Court rejects Big Pharma appeals challenging negotiated drug prices in Medicare

Supreme Court Dismisses Legal Challenges to Medicare Drug Price Negotiations

Supreme Court rejects Big Pharma appeals – The U.S. Supreme Court has turned down appeals from major pharmaceutical companies seeking to overturn a policy designed to cut federal healthcare expenditures. The decision, made on Monday, preserves the program established by Congress in 2022, which empowers Medicare to secure lower prices for select medications. This initiative is anticipated to generate substantial savings for taxpayers, potentially saving billions of dollars annually by requiring drugmakers to engage in price negotiations. The Court’s rejection of the appeals came without elaboration, leaving the rulings from lower courts intact.

Medicare’s New Pricing Mechanism

Since 2022, Medicare has been allowed to negotiate drug prices for the first time, a provision introduced through the Inflation Reduction Act. This measure aims to address years of rising prescription costs, which have placed significant strain on both the government and its beneficiaries. The program’s implementation has sparked legal battles, with pharmaceutical giants like AstraZeneca and Janssen arguing it undermines their rights. However, the Supreme Court’s recent ruling has given the policy a green light, pending further challenges.

Under the program, Medicare identifies drugs with the highest spending levels and negotiates prices with manufacturers. The first round of negotiations involved ten medications, including Farxiga (AstraZeneca) and Eliquis (Bristol Myers Squibb), which are used to treat diabetes, heart disease, kidney disease, blood clots, and strokes. The Biden administration reported that these initial agreements would result in $6 billion in federal savings and a $1.5 billion reduction in seniors’ out-of-pocket expenses by January 2024. The second round, covering fifteen drugs, is projected to save Medicare approximately $12 billion, with additional cost cuts for beneficiaries expected by next January, according to the Trump administration’s November assessment.

Pharmaceutical Industry’s Legal Arguments

Drugmakers have mounted a multifaceted defense against the program, asserting that it infringes on their constitutional rights. They claim the negotiation process amounts to a “sham” that denies them due process, arguing that the discounts forced upon them are not legitimate but rather government-imposed price controls. Some companies also contend that the program violates the First Amendment, as it compels them to accept a government narrative about fair pricing, even if they disagree.

“The challenges that the industry presented were weak in law. They were grasping at constitutional straws,” said Andrew Twinamatsiko, director of the Center for Health Policy and the Law at Georgetown University’s O’Neill Institute.

Twinamatsiko and a colleague detailed these arguments in a Health Affairs article published in March, stating that federal courts have consistently ruled in favor of the program. They emphasized that the legal basis for the challenges is shaky, with judges highlighting that participation in Medicare is voluntary and companies can withdraw if they are dissatisfied with the negotiated prices.

Among the key legal points raised by manufacturers is the claim that they are being forced to give up their drugs to Medicare without adequate compensation. This argument hinges on the idea that the program constitutes an unconstitutional “taking” under the Fifth Amendment. If companies refuse to accept the government’s price, they face the dilemma of either exiting Medicare and Medicaid, which are vast markets for the industry, or paying steep excise taxes. Critics argue these options leave the companies with no real choice but to comply with the terms.

Historical Context and Ongoing Legal Battles

Legal disputes over the program have been unfolding for three years, with multiple cases filed in different federal districts. So far, all decisions have favored the government, reinforcing that the negotiation process is lawful and that drugmakers can opt out if necessary. The Supreme Court, however, is often cautious in cases where there isn’t a split among lower courts. In this instance, the pharmaceutical companies lacked such support, making it harder to persuade the justices to intervene.

The program’s impact is evident in the figures cited by the Trump administration, which noted that in 2021 alone, over $250 billion was spent on Medicare-covered drugs. This underscores the urgency of the policy, as the financial burden continues to grow. For Farxiga, a drug highlighted in the negotiations, AstraZeneca admitted that the government secured a 68% discount from its list price, a move that has been widely praised for its cost-saving potential.

Next Steps and Broader Implications

Negotiations for the third round of drugs are currently underway, with the goal of expanding the program’s reach. The process of selecting drugs is based on their total Medicare spending, ensuring that the most expensive medications are prioritized for price reductions. While the industry remains unconvinced, the courts have repeatedly upheld the policy, signaling that the government’s authority to negotiate is well-established.

The Supreme Court’s decision to reject the appeals marks a significant victory for the Biden administration and Medicare beneficiaries. It also sets a precedent that could influence future debates on drug pricing. As the program continues, pharmaceutical companies will need to adapt, either by accepting the negotiated prices or exploring alternative strategies to mitigate the financial impact. The ruling reaffirms the government’s role in controlling costs, even as the industry pushes back with legal and economic arguments.

With the legal landscape now clearer, the focus shifts to the program’s long-term effectiveness. Advocates argue that it will lead to sustained savings, while critics warn of potential market distortions. Regardless of the outcome, the Supreme Court’s stance has provided a crucial boost to the policy, ensuring its implementation proceeds without immediate obstruction. The drug price negotiations represent a bold attempt to rein in costs, and their success will depend on how well the program balances the interests of patients, the government, and the pharmaceutical industry.